Assistant Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Ian E. Krop, MD
|
|
Give Review
Ian E. Krop practices Oncology. He went to medical school at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical university. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. Krop is a published MD as well. He has 45 publications published. The latest was: Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorse... He accepts all Medicare patients.
Publications
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast C...
- PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity.
- The Evolving Landscape of HER2 Targeting in Breast Cancer.
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus ...
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in Breast cancer patients.
- PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient Breast cancers.
- Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
- Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Po...
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive Breast cancer.
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic Breast ca...
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society...
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Gu...
- New Research on the Treatment of Small HER2-Positive Breast Cancers.
- Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer.
- A phase II study of preoperative capecitabine in women with operable hormone receptor positive Breast cancer.
- Prospective clinical experience with research biopsies in Breast cancer patients.
- Pertuzumab: optimizing HER2 blockade.
- Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive Breast cancer with prolonged clinical benefit to first-line trastuzu...
- A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive Breast cancer.
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic Breast cancer.
- An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling ...
- Prevalence of germline TP53 mutations in HER2+ Breast cancer patients.
- Targeted therapies: HER2-positive Breast cancer-sifting through many good options.
- A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive Breast cancer.
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer.
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
- Use of discard Pleural fluid in molecular research.
- The ethical use of mandatory research biopsies.
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Bas...
- A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and Brain Metastases.
- Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer.
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive Breast cancer after prior H...
- Advances in targeting SRC in the treatment of Breast cancer and other solid malignancies.
- Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic Breast cancer.
- Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes Breast cancer cells to ErbB2 antagonists.
- Epithelial and stromal cathepsin K and CXCL14 expression in Breast tumor progression.
- Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive Breast cancers.
- Does MRI predict pathologic tumor response in women with Breast cancer undergoing preoperative chemotherapy?
- Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?
- Ovarian suppression for Breast cancer: an effective treatment in search of a home.
- Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.
- Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorse...
Schools
Johns Hopkins University School Of Medicine
Johns Hopkins Hospital
Dana Farber Cancer Institute
Conditions Treated
- Anemia
- Breast Cancer
- Carcinoma in Situ
- Colorectal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- GEHA
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Neighborhood Health Plan
- Tufts Health Plans
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Brigham and Women's Hospital -
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1033187455 | |
| NPPES Provider LastName | KROP | |
| NPPES Provider FirstName | IAN | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 65.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033187455 |
| Last Name Of The Provider | KROP |
| First Name Of The Provider | IAN |
| View All |
Similar Doctors
|
|
Dr. Robert H. Gottlieb, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas J. Schuetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susana M. Campos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pasi A. Janne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harold J. Burstein, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert J. Soiffer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
|